IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens

Table 3

Baseline characteristics and treatment response in 37 patients treated with peginterferon, ribavirin, and telaprevir according to IFNL4 ss469415590 variant.

	IFNL4 major,	IFNL4 minor,	values (major versus minor groups)
Gender, male/female	19/5	9/4	0.78
Age, years	59.5 ± 7.7	55.2 ± 10.2	0.15
Previous treatment: naïve/relapse/null	10/13/1	7/4/2	0.71
AST, IU/L	50.9 ± 48.9	59.8 ± 44.2	0.58
ALT, IU/L	63.8 ± 60.5	77.9 ± 77.2	0.54
γ-GTP, IU/L	51.8 ± 52.2	78.6 ± 73.3	0.25
Hemoglobin, g/dL	14.6 ± 1.2	14.5 ± 1.3	0.81
Platelets, ×10^4/mm^3	15.9 ± 5.2	16.5 ± 5.3	0.74
HCV RNA ()	6.70 ± 0.54	6.18 ± 0.87	0.0309
Treatment response
RVR,	17	8	0.83
EVR,	22	10	0.45
SVR/relapse/null	22	8	0.0727

Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.